FindTrial
Sign In

Clinical Effectiveness and Safety of Zebtilimab for CD20-Positive Diffuse Large B-Cell Lymphoma: A Prospective, Non-Interventional, Decentralized Real-World Evidence Study

Clinical Effectiveness and Safety of Zebtilimab for CD20-Positive Diffuse Large B-Cell Lymphoma: A Prospective, Non-Interventional, Decentralized Real-World Evidence Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101219
Enrollment
Unknown
Registered
2025-04-22
Start date
2025-04-30
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CD20 positive diffuse large B cell lymphoma

Interventions

Zuberitamab treatment group:NA

Sponsors

Affiliated hangzhou first people's hospital, zhejiang university school of medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Voluntary signing of the informed consent form; 2. Age >= 18 years, with no gender restrictions; 3. Diagnosis of diffuse large B-cell lymphoma (DLBCL) with CD20 positivity confirmed by immunohistochemistry;

Exclusion criteria

Exclusion criteria: 1. The physician determines that participation in the study is not in the best interest of the patient, or any other condition that would prevent the safe implementation of the protocol; 2. This study is a real-world study and has no other specific exclusion criteria.

Design outcomes

Primary

MeasureTime frame
Complete Response Rate;—

Secondary

MeasureTime frame
objective response rate;1-3 year PFS rate;1-3 year OS rate;safety;—

Countries

China

Contacts

Public ContactXiangmin Tong

Affiliated hangzhou first people's hospital, zhejiang university school of medicine

tongxiangmin@163.com+86 571 85893643

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026